Zacks Research Weighs in on AstraZeneca PLC’s Q2 2025 Earnings (NASDAQ:AZN)

AstraZeneca PLC (NASDAQ:AZN) – Equities research analysts at Zacks Research cut their Q2 2025 EPS estimates for shares of AstraZeneca in a research note issued to investors on Wednesday, April 17th. Zacks Research analyst R. Department now forecasts that the company will earn $1.14 per share for the quarter, down from their prior estimate of $1.15. The consensus estimate for AstraZeneca’s current full-year earnings is $4.02 per share. Zacks Research also issued estimates for AstraZeneca’s Q3 2025 earnings at $1.17 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.63 EPS, Q1 2026 earnings at $1.20 EPS and FY2026 earnings at $5.09 EPS.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.73 earnings per share for the quarter, missing the consensus estimate of $0.74 by ($0.01). The business had revenue of $12.02 billion for the quarter, compared to analyst estimates of $12.07 billion. AstraZeneca had a return on equity of 30.19% and a net margin of 13.00%. AstraZeneca’s revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.69 EPS.

Other research analysts have also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday. Jefferies Financial Group cut shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. Finally, Morgan Stanley assumed coverage on shares of AstraZeneca in a research report on Tuesday, January 23rd. They issued an “overweight” rating for the company. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $80.00.

AstraZeneca Price Performance

NASDAQ AZN opened at $68.36 on Thursday. AstraZeneca has a 52 week low of $60.47 and a 52 week high of $76.56. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.57. The stock has a market cap of $211.94 billion, a price-to-earnings ratio of 35.60, a price-to-earnings-growth ratio of 1.25 and a beta of 0.50. The company has a 50-day moving average price of $66.12 and a two-hundred day moving average price of $65.87.

AstraZeneca Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Monday, March 25th. Stockholders of record on Friday, February 23rd were issued a $0.965 dividend. The ex-dividend date of this dividend was Thursday, February 22nd. This is a boost from AstraZeneca’s previous Semi-Annual dividend of $0.47. This represents a dividend yield of 2.3%. AstraZeneca’s dividend payout ratio (DPR) is 100.52%.

Institutional Trading of AstraZeneca

A number of large investors have recently added to or reduced their stakes in the business. SeaCrest Wealth Management LLC boosted its holdings in AstraZeneca by 2.5% during the first quarter. SeaCrest Wealth Management LLC now owns 17,354 shares of the company’s stock worth $1,176,000 after buying an additional 420 shares in the last quarter. Naviter Wealth LLC lifted its position in shares of AstraZeneca by 33.5% in the 1st quarter. Naviter Wealth LLC now owns 63,162 shares of the company’s stock valued at $4,279,000 after acquiring an additional 15,834 shares in the last quarter. Quattro Financial Advisors LLC lifted its position in shares of AstraZeneca by 7,362.7% in the 1st quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the company’s stock valued at $339,000 after acquiring an additional 4,933 shares in the last quarter. Cullinan Associates Inc. lifted its position in shares of AstraZeneca by 13.0% in the 1st quarter. Cullinan Associates Inc. now owns 13,026 shares of the company’s stock valued at $883,000 after acquiring an additional 1,498 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of AstraZeneca by 172.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 10,496 shares of the company’s stock valued at $711,000 after acquiring an additional 6,650 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.